Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2008

View Archived Issues

Pfizer develops new series of PDE5 inhibitors for once-daily dosing

TRO-40303 demonstrates cardioprotective effects after ischemia-reperfusion in vivo

Novel prodrugs for HCV may represent an improvement over valopicitabine

Bionomics presents data on novel vascular disruption agents for cancer

Recent patents disclose novel analgesic agents

TRITON-TIMI 38: Prasugrel reduces recurrent cardiovascular events

Allopurinol lowers blood pressure in adolescents with hypertension

Abraxis and ProMetic enter worldwide agreements for four biopharmaceuticals

Cytokinetics initiates dosing in phase IIa clinical trial of CK-1827452 in stable heart failure

Nanotherapeutics submits IND to FDA for phase IIa clinical study of NanoDOX

FDA schedules advisory committee meeting with Novo Nordisk for liraglutide NDA

Submicromolar Hsp90 inhibitors identified by TopoTarget

Medarex receives milestone payment from Pfizer following filing of IND with FDA

FDA approves TopoTarget's SPA for a phase III trial of belinostat in PTCL

AMRI and BMS select second compound for clinical development for CNS diseases

Pro-Pharmaceuticals submits data to FDA for pre-IND meeting on antihypoxia drug

Recent IRM and AstraZeneca patents report new agents for treating respiratory disorders

Novel treatments for diabetes and related disorders disclosed in recent patents

Pfizer to withdraw global marketing applications for dalbavancin in order to conduct phase III trial

Oramed signs agreement with ETI Karle Clinical to conduct a phase IIb clinical trial of ORMD-0801

Oxford BioMedica reports positive interim results from phase I/II trial of ProSavin in Parkinson's

RegeneRx reports results from phase Ia clinical trial of RGN-352 in healthy subjects

Epiphany presents a report on the clinical development of valomaciclovir in herpes zoster

FDA accepts inhaled treprostinil NDA for review

Schering-Plough launches Bridion in Europe

Data indicate CEL-2000 vaccine prevents or retards permanent damage of RA

PainCeptor presents clinical results for PPC-5650 in pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...